Kraig Biocraft Laboratories (KBLB) 10-K 27 Mar 20 2019 FY Annual report Financial data

Document Entity Information

Document Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 27, 2020	Jun. 30, 2019
Document Entity Information
Entity Registrant Name	Kraig Biocraft Laboratories, Inc
Entity Central Index Key	0001413119
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 258,965,870
Entity Common Stock, Shares Outstanding		844,468,378
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash	$ 125,024	$ 13,697
Prepaid expenses	31,745	6,858
Total Current Assets	156,769	20,555
Property and Equipment, net	117,321	47,310
Operating lease right-of-use asset, net	473,242
Security deposit	3,518	3,518
Total Assets	750,850	71,383
Current Liabilities
Accounts payable and accrued expenses	560,948	793,482
Note payable - related party	642,000	322,000
Royalty agreement payable - related party	65,292	65,292
Accounts payable and accrued expenses - related party	4,145,465	3,349,832
Operating lease liability, current	110,678
Loan payable	60,000
Total Current Liabilities	5,584,383	4,530,606
Long Term Liabilities
Loan payable, net of current	185,244
Operating lease liability, net of current	369,281
Total Liabilities	6,138,908	4,530,606
Commitments and Contingencies
Stockholders' Deficit
Preferred stock Series A, no par value; 2 and 2 shares issued and outstanding, respectively	5,217,800	5,217,800
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	22,000	22,000
Additional paid-in capital	2,412,969	2,043,235
Accumulated Deficit	(29,797,906)	(26,888,056)
Total Stockholders' Deficit	(5,388,058)	(4,459,223)
Total Liabilities and Stockholders' Deficit	750,850	71,383
Class A Common Stock [Member]
Stockholders' Deficit
Common stock, value	16,757,079	15,145,798
Common Stock Class B [Member]
Stockholders' Deficit
Common stock, value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value
Preferred stock, shares issued	2	2
Preferred stock, shares outstanding	2	2
Common stock issuable	1,122,311	1,122,311
Class A Common Stock [Member]
Common stock, par value
Common stock, shares issued	844,468,378	816,883,910
Common stock, shares outstanding	844,468,378	816,883,910
Common Stock Class B [Member]
Common stock, par value
Common stock, shares issued
Common stock, shares outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue		$ 401,620
Operating Expenses
General and Administrative	1,413,982	515,875
Professional Fees	342,845	157,976
Officer's Salary	627,197	528,127
Rent - Related Party	14,793	11,520
Research and Development	223,050	148,069
Total Operating Expenses	2,621,867	1,361,567
Loss from Operations	(2,621,867)	(959,947)
Other Income/(Expenses)
Gain on forgiveness of debt		19,924
Interest expense	(294,352)	(228,954)
Interest income	6,369
Total Other Income/(Expenses)	(287,983)	(209,030)
Net (Loss) before Provision for Income Taxes	(2,909,850)	(1,168,977)
Provision for Income Taxes
Net (Loss)	$ (2,909,850)	$ (1,168,977)
Net Income (Loss) Per Share - Basic and Diluted	$ 0	$ 0
Weighted average number of shares outstanding during the period - Basic and Diluted	835,587,422	816,874,442

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities:
Net Loss	$ (2,909,850)	$ (1,168,977)
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense	30,781	26,632
Gain on forgiveness of debt		(19,924)
Imputed interest - related party	22,337	11,909
Fair value of options issued for services	696,934
Warrants issued/(cancelled) to consultants	(19,915)	72,575
Changes in operating assets and liabilities:
Increase in prepaid expenses	(24,887)	(2,394)
(Increase) in accounts receivables, net		25,872
Operating lease right-of-use, net	86,326
Increase in accrued expenses and other payables - related party	795,633	682,976
Increase (Decrease) in accounts payable	314,369	136,326
Operating lease liabilities, current	(79,609)
Net Cash Used In Operating Activities	(1,087,881)	(235,005)
Cash Flows From Investing Activities:
Purchase of Fixed Assets and Domain Name	(100,792)	(11,448)
Net Cash Used In Investing Activities	(100,792)	(11,448)
Cash Flows From Financing Activities:
Proceeds from Notes Payable - related party	320,000	242,000
Principal payments on debt	(20,000)
Proceeds from issuance of common stock	1,000,000
Net Cash Provided by Financing Activities	1,300,000	242,000
Net Increase in Cash	111,327	(4,453)
Cash at Beginning of Year	13,697	18,150
Cash at End of Year	125,024	13,697
Supplemental disclosure of cash flow information:
Cash paid for interest		10
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Shares issued in connection with cashless warrants exercise	329,622
Settlement of accounts payable with note payable	265,244
Settlement of accounts payable with stock issuance	281,659	1,076
Adoption of lease standard ASC 842	$ 559,568

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders Deficit (Unaudited) - USD ($)	Preferred Stock - Series A [Member]	Common Stock - Class A [Member]	Common Stock - Class B [Member]	Common Stock - Class A Shares to Be Issued [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2017	$ 5,217,800	$ 15,144,722		$ 22,000	$ 1,958,751	$ (25,719,079)	$ (3,375,806)
Beginning Balance, shares at Dec. 31, 2017	2	816,847,910		1,122,311
Warrants issued for services					72,575		72,575
Stock issued for services ($0.0299/Sh)		$ 1,076					1,076
Stock issued for services ($0.0299/Sh), shares		36,000
Imputed interest - related party					11,909		11,909
Net loss for the year ended						(1,168,977)	(1,168,977)
Ending Balance at Dec. 31, 2018	$ 5,217,800	$ 15,145,798		$ 22,000	2,043,235	(26,888,056)	(4,459,223)
Ending Balance, shares at Dec. 31, 2018	2	816,883,910		1,122,311
Imputed interest - related party					22,337		22,337
Units issued for cash		$ 1,000,000					1,000,000
Units issued for cash, shares		14,797,278
Shares issued in exchange for accounts payable		$ 281,659					281,659
Shares issued in exchange for accounts payable, shares		4,052,652
Options issued for services					696,934		696,934
Exercise of 9,000,000 warrants in exchange for stock		$ 329,622			(329,622)
Exercise of 9,000,000 warrants in exchange for stock, shares		8,734,538
Cancellation of warrants issued for services					(19,915)		(19,915)
Net loss for the year ended						(2,909,850)	(2,909,850)
Ending Balance at Dec. 31, 2019	$ 5,217,800	$ 16,757,079		$ 22,000	$ 2,412,969	$ (29,697,906)	$ (5,388,058)
Ending Balance, shares at Dec. 31, 2019	2	844,468,378		1,122,311

Consolidated Statement of Cha_2

Consolidated Statement of Changes in Stockholders Deficit (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Stockholders' Equity [Abstract]
Exercise of warrants	9,000,000	9,000,000
Share price	$ 0.0299	$ 0.0299

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On October 8, 2019, the Company delivered the first batch of its transgenic silkworm eggs to its production factory in Quang Nam, Vietnam for the purpose of commencing production at that facility. On November 4, 2019, the Company reported that it had successfully completed rearing the first batch of its transgenic silkworms at its production factory in Quang Nam, Vietnam. The Company expects to continue expanding production of its specialized silk. In January 2020, the Company reported challenges related to climate and access to high quality mulberry during the winter months at its subsidiary in Vietnam. The Company announced that it had already begun planting additional mulberry fields to ensure no future shortages. (B) Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date. (C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. (D) Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents as of December 31, 2019 or December 31, 2018. (E) Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For December 31, 2019 and December 31, 2018, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for December 31, 2019 and December 31, 2018 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: December 31, 2019 December 31, 2018 Stock Warrants (Exercise price - $0.001-$0.2299/share) 55,995,917 36,400,000 Convertible Preferred Stock 2 2 Total 55,995,919 36,400,002 (F) Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation. (G) Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: 2019 2018 Expected income tax recovery (expense) at the statutory rate of 21% $ (610,845 ) $ (1,412,328 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 142,167 11,057 Change in valuation allowance (468,678 ) (1,423,384 ) Provision for income taxes $ - $ - The components of deferred income taxes are as follows: Years Ended December, 2019 2018 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 3,379,542 2,910,863 Valuation allowance (3,379,542 ) (2,910,863 ) Net deferred tax asset - - Net deferred tax liability $ - $ - The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2039. The net change in the valuation allowance for the year ended December 31, 2019 and 2018 was an increase of $610,845 and a decrease of $1,412,328, respectively. Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model. (H) Stock-Based Compensation In December 2004, the FASB issued FASB ASC No. 718, Compensation – Stock Compensation Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by FASB ASC No. 718. FASB ASC No. 505, Equity Based Payments to Non-Employees (I) Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11 on its financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. The 2018 financial statements have been reclassified to conform to the 2019 presentation. (J) Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. The Company uses a five year life for automobiles. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no impairment losses recorded for the years ended December 31, 2019 and 2018. (K) Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “ Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2019 and December 31, 2018. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. December 31, 2019 December 31, 2018 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ - (L) Revenue Recognition During the year ended December 31, 2018, the Company’s revenues were generated primarily from a contract with the U.S. Government. The Company performs work under this cost-plus-fixed-fee contract. Under the base phase of that contract the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017, to that original contract, the Company has worked to develop new recombinant silks. This contract ended in September of 2018. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC No. 605 — Revenue Recognition. Under ASC No. 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists;(2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. For the years ended December 31, 2019 and 2018, the Company recognized $0 and $401,620 respectively in revenue from the Government contract. These revenues were generated for work performed in the development and production of the Company’s recombinant silks under the base and option period phases of our ongoing contract with the US Army. On July 24, 2017, the Company signed a contract option extension with the US Army to research and deliver recombinant spider silk fibers and threads. This contract option increased the total contract award by an additional $921,130 to a total of $1,021,092 and added 12 months to the contract duration. This effort was scheduled to end on September 24, 2018, but the Company requested an extension of this contract option period through April 2019 to complete the work. The Company has been in communication with the contracting office and is working with them as they determine the best path forward; Management believes there is a possibility of securing a follow-up contract to complete the delivery of all materials for the contract. The Company is also continuing to pursue additional contract opportunities with the Department of Defense, Department of Energy and other governmental agencies. (M) Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2019 and December 31, 2018, the Company had approximately $0 and $0, respectively in excess of FDIC insurance limits. For the years ended December 31, 2019 and 2018, the Company had a concentration of sales of: December 31, 2019 December 31, 2018 Customer Customer A - 100 % Customer A $ - $ 401,620 For the years ended December 31, 2019 and 2018, the Company booked $0 and $0 for doubtful accounts.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 GOING CONCERN As reflected in the accompanying financial statements, the Company has a working capital deficiency of $5,427,614 and stockholders’ deficiency of $5,388,058 and used $1,087,881 of cash in operations for year ended December 31, 2019. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Equipment	NOTE 3 EQUIPMENT At December 31, 2019 and December 31, 2018, property and equipment, net, is as follows: December 31, 2019 December 31, 2018 Automobile $ 41,805 $ 41,805 Laboratory Equipment 96,536 73,194 Office Equipment 7,260 7,260 Leasehold Improvements 85,388 7,938 Less: Accumulated Depreciation (113,668 ) (82,887 ) Total Property and Equipment, net $ 117,321 $ 47,310 Depreciation expense for the years ended December 31, 2019 and 2018, was $30,781 and $26,632, respectively.

Right to Use Assets and Lease L

Right to Use Assets and Lease Liability	12 Months Ended
	Dec. 31, 2019
Right To Use Assets And Lease Liability
Right to Use Assets and Lease Liability	NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITITY Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $2,508 for conference facilities, mail, fax, and reception services located at our principal place of business. On January 23, 2017, the Company signed an 8 year property lease with the Company’s President for land in Texas where the Company grows its mulberry. The Company pays a monthly rent of $960. Rent expense – related party for the years ended December 31, 2019 and 2018, was $11,913 and $5,760, respectively (See Note 9). On September 13, 2017, the Company signed a new two year lease commencing on October 1, 2017 and ending on December 31, 2019. The Company pays an annual rent of $39,200 for the year one of lease and $42,000 for the year two of lease for office and manufacturing space. On September 5, 2019, the Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters. The Company pays an annual rent of $42,000 for year one of the lease and $44,800 for year two of the lease. On May 9, 2019, the Company signed a 5 year property lease with the Socialist Republic of Vietnam which consists of 4,560.57 square meters of space, which it leases at a current rent of approximately $45,150 per year one and two and with the 5% increase per year for years three through five. In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases The Company adopted the new lease guidance effective January 1, 2019 using the modified retrospective transition approach, applying the new standard to all of its leases existing at the date of initial application which is the effective date of adoption. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. We elected the package of practical expedients which permits us to not reassess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases, and (3) any initial direct costs for any existing leases as of the effective date. We did not elect the hindsight practical expedient which permits entities to use hindsight in determining the lease term and assessing impairment. The adoption of the lease standard did not change our previously reported consolidated statements of operations and did not result in a cumulative catch-up adjustment to opening equity. The adoption of the new guidance resulted in the recognition of ROU assets of $559,568 and lease liabilities of $559,568. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. In calculating the present value of the lease payments, the Company elected to utilize its incremental borrowing rate based on the remaining lease terms as of the January 1, 2019 adoption date. This rate was determined to be 8% and the Company determined the initial present value, at inception, of $559,568. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred, if any. The Company has elected the practical expedient to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, current operating lease liabilities and non-current operating lease liabilities. The new standard also provides practical expedients and certain exemptions for an entity’s ongoing accounting. We have elected the short- term lease recognition exemption for all leases that qualify. This means, for those leases where the initial lease term is one year or less or for which the ROU asset at inception is deemed immaterial, we will not recognize ROU assets or lease liabilities. Those leases are expensed on a straight line basis over the term of the lease Right to use assets is summarized below: December 31, Right to use assets, net – related party $ 69,884 Right to use assets, net 53,799 Right to use assets, net 349,559 Total $ 473,242 During the year ended December 31, 2019, the Company recorded $75,575 as lease expense to current period operations. During the year ended December 31, 2019, the Company recorded $11,913 as lease expense – related party to current period operations. Lease liability is summarized below: December 31, Right to use liability, net – related party 55,372 Right to use liability, net 70,901 Right to use liability, net 353,686 Total 479,959 Less: short term portion $ (110,678 ) Long term position $ 369,281 Lease expense for the year ended December 31, 2019 was comprised of the following: Operating lease expense $ 43,666 Operating lease expense $ 64,327 Operating lease expense – related party $ 14,793

Accrued Interest - Related Part

Accrued Interest - Related Party	12 Months Ended
	Dec. 31, 2019
Accrued Interest - Related Party
Accrued Interest - Related Party	NOTE 5 ACCRUED INTEREST – RELATED PARTY On June 6, 2016, the Company received a $50,000 loan from our principal stockholder. Subsequently on December 1, 2017, the Company received an additional $30,000 loan from the same stockholder. On January 8, 2018 and March 31, 2018 the Company received an additional loan of $100,000 and $15,000, respectively. The Company received additional loan funds from the same stockholder as follows: $20,000 on April 26, 2018; $15,000 on June 21, 2018; $15,000 on June 29, 2018; $20,000 on July 5, 2018; $26,000 on October 1, 2018; $11,000 on October 12, 2018; $20,000 on December 21, 2018; $3,000 on January 4, 2019; $30,000 on January 17, 2019; $30,000 on February 1, 2019; $20,000 on February 15, 2019; $20,000 on March 1, 2019; $17,000 on January 4, 2019, $100,000 on November 20, 2019 and $100,000 on December 18, 2019. Pursuant to the terms of the loan, the advance bears an interest at 3%, is unsecured, and due on demand. Total loan payable to principal stockholder for as of December 31, 2018 is $322,000. Total loan payable to this principal stockholder as of December 31, 2019 is $642,000. During the year ended December 31, 2019, the Company recorded $22,337 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $15,581. During the year ended December 31, 2018, the Company recorded $11,909 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $7,071.

Note Payable

Note Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Note Payable	NOTE 6 NOTE PAYABLE On March 1, 2019, the Company entered into an unsecured promissory note with Notre Dame - an unrelated party in the amount of $265,244 in exchange for outstanding account payable due to the debtor. Pursuant to the terms of the note, the note bears 10% interest per year from the date of default until the date the loan is paid in full. The term of the loan is twenty four months. The loan repayment commenced immediately over a twenty-four month period according to the following table. During the year ended December 31, 2019, the Company paid $20,000 of the loan balance (See Note 8 (A): 1. $1,000 per month for the first six months; 2. $2,000 per month for the months seven and eight; 3. $5,000 per month for months nine through twenty three; and, 4. Final payment of all remaining balance, in the amount of $180,224 in month 24.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Deficit	NOTE 7 STOCKHOLDERS’ DEFICIT (A) Common Stock Issued for Cash On March 9, 2019, the Company entered into a purchase agreement with one investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued the investor 14,797,278 Units at a purchase price of $0.06758 per Unit, for total gross proceeds to the Company of $1,000,000. The Units consist of 14,797,278 shares of the Company’s Class A Common Stock (the “Common Stock”) and two warrants (the “Warrants”): (i) one warrant entitles the investor to purchase up to 14,797,278 shares of Common Stock at an exercise price of $0.06 per share (the “6 Cent Warrants”) and (ii) one warrant entitles the investor to purchase up to 7,398,639 shares of Common Stock at an exercise price of $0.08 per share (the “8 Cent Warrant”). The Warrants shall be exercisable at any time from the issuance date until the following expiration dates: ●½ of all $0.06 Warrants shall expire on March 8, 2021; ●½ of all $0.06 Warrants shall expire on March 8, 2022; ●½ of all $0.08 Warrants shall expire on March 8, 2022; and, ●½ of all $0.08 Warrants shall expire on March 8, 2023. (B) Common Stock Issued for Services Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant. On March 20, 2019, the Company issued 4,052,652 shares of its class A common stock with a fair value of $281,659 ($0.0695/share) on the date of settlement. The Company settled $243,159 of accounts payable to the University of Notre Dame. The Company recorded an additional amount of $38,500 based on the fair value of the shares on the date of settlement. See Note 8 (A). On April 6, 2018, the Company issued 36,000 shares with a fair value of $1,076 ($0.0299/share) to a consultant as consideration for consulting fees owed from October 1, 2014 through December 31, 2018 of $21,000. The issuance of shares resulted in gain on settlement of accounts payable of $19,924. See Note 8(B). On March 20, 2018, the Company issued 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018. This warrant was cancelled on April 4, 2019 for a cash payment of $6,000. (C) Common Stock Warrants and Options On September 26, 2019, the Company issued 766,667 shares in connection with the cashless exercise of the 1,000,000 warrants. On August 14, 2019, the Company issued 7,967,871 shares in connection with the cashless exercise of the 8,000,000 warrants. On August 8, 2019, the Company issued a 2-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $267,574, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2024. During the year ended December 31, 2019, the Company recorded $267,574 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $267,574, based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2020. Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025. During the year ended December 31, 2019, the Company recorded $106,006 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 3-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $291,842, based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the year ended December 31, 2019, the Company recorded $57,889 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Years Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 1,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $118,874, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023. During the year ended December 31, 2019, the Company recorded $118,874 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 1,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $118,874, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2021, and for a period of 3 years expiring on August 8, 2024. During the year ended December 31, 2019, the Company recorded $118,874 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to an employee for services rendered. The options had a fair value of $14,859, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023. During the year ended December 31, 2019, the Company recorded $14,859 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $16,723, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2020. Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025. During the year ended December 31, 2019, the Company recorded $6,625, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $18,240, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the year ended December 31, 2019, the Company recorded $3,618, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Years Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $19,525, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2022. Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027. During the year ended December 31, 2019, the Company recorded $2,615, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Years Risk free interest rate 1.54 % Expected forfeitures 0 % On March 20, 2018, the Company issued a 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018. Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022. During the year ended December 31, 2018, the Company recorded $19,915 as an expense for warrants issued. On April 5, 2019, the Company cancelled 600,000 warrant issued to a consultant on February 20, 2018 in exchange for $6,000 cash payment. In addition the Company also recorded a $19,915 reduction to warrant expense related to the warrant cancellation. Expected dividends 0 % Expected volatility 97.56 % Expected term 4 Years Risk free interest rate 2.65 % Expected forfeitures 0 % On February 9, 2018, the Company issued a 3-year o to purchase 3,000,000 shares of common stock at an exercise price of $0.056 per share to a consultant for services rendered. The options had a fair value of $52,660, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 9, 2019, and for a period of 2 years expiring on August 9, 2021. During the year ended December 31, 2018, the Company recorded $52,660 as an expense for options issued. Expected dividends 0 % Expected volatility 96.95 % Expected term 3 Years Risk free interest rate 2.26 % Expected forfeitures 0 % Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Balance as of December 31, 2018 34,300,000 3.0 Granted 30,695,917 2.94 Exercised (9,000,000 ) Cancelled/Forfeited (600,000 ) Balance, December 31, 2019 55,395,917 2.77 Intrinsic Value $ 10,852,009 For the year ended December 31, 2019, the following warrants were outstanding: Exercise Price Warrants Outstanding Warrants Exercisable Weighted Average Remaining Contractual Life Aggregate Intrinsic Value $ 0.001 21,000,000 1.65 $ 4,069,800 $ 0.056 3,000,000 1.61 $ 387,600 $ 0.04 2,300,000 1.70 $ 445,740 $ 0.06 7,398,639 1.19 $ 1,433,856 $ 0.06 7,398,639 2.19 $ 1,433,856 $ 0.08 3,699,320 2.19 $ 716,928 $ 0.08 3,699,320 3.19 $ 719,928 $ 0.2299 8,500,000 5.39 $ 1,647,300 For the year ended December 31, 2018, the following warrants were outstanding: Exercise Price Warrants Outstanding Warrants Exercisable Weighted Average Remaining Contractual Life Aggregate Intrinsic Value $ 0.001 29,600,000 2.9 $ 1,523,900 $ 0.056 3,000,000 2.6 $ 147,000 $ 0.04 2,300,000 2.7 $ 112,700 (D) Amendment to Articles of Incorporation On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows: ●Common stock Class A, unlimited number of shares authorized, no par value ●Common stock Class B, unlimited number of shares authorized, no par value ●Preferred stock, unlimited number of shares authorized, no par value Effective December 17, 2013, the Company amended its articles of incorporation to designate a Series A no par value preferred stock. Two shares of Series A Preferred stock have been authorized and were issued (E) Common Stock Issued for Debt None

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 8 COMMITMENTS AND CONTINGENCIES On November 10, 2010, the Company entered into an employment agreement with its CEO, effective January 1, 2011 through the December 31, 2015. The term of the agreement is a five year period at an annual salary of $210,000. There is a 6% annual increase. For the year ending December 31, 2015, the annual salary was $281,027. The employee is also to receive a 20% bonus based on the annual based salary. Any stock, stock options bonuses have to be approved by the board of directors. On January 1, 2016 the agreement was renewed with the same terms for another 5 years with an annual salary of $297,889 for the year ended December 31, 2016. On January 1, 2017 the agreement renewed with the same terms for another 5 years, but with an annual salary of $315,764 for the year ended December 31, 2017. On January 1, 2019 the agreement renewed again with the same terms for another 5 years, but with an annual salary of $354,791 for the year ended December 31, 2018. As of December 31, 2019 and December 31, 2018, the accrued salary balance is $2,535,203 and $2,109,454, respectively. (See Note 9). On January 20, 2015, the board of directors appointed Mr. Jonathan R. Rice as our Chief Operating Officer. Mr. Rice’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to an annual cash compensation of $120,000, which includes salary, health insurance, 401K retirement plan contributions, etc. The Company also agreed to reimburse Mr. Rice for his past educational expenses of approximately $11,000. In addition, Mr. Rice was issued a three-year warrant to purchase 2,000,000 shares of common stock of the Company at an exercise price of $0.001 per share (the “January 2015 Warrant”) pursuant to the employment agreement. Additionally, on May 28, 2015, the Company issued a three-year warrant to purchase 3,000,000 shares of common stock of the Company at an exercise price of $0.001 per share (the “May 20165 Warrant”) to Mr. Rice. The 2,000,000 share warrant fully vested on October 28, 2016. For the year ended December 31, 2015, the Company recorded $121,448 for the warrants issued to Mr. Rice. On January 14, 2016, the Company signed a new employment agreement with Mr. Rice. The employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to annual cash compensation of $140,000, which includes salary, health insurance, 401K retirement plan contributions, etc. In addition, Mr. Rice was issued a three-year warrant to purchase 6,000,000 shares of common stock of the Company at an exercise price of $0.001 per share pursuant to the employment agreement. For the year ended December 31, 2016, the Company recorded $193,652 for the warrants issued to Mr. Rice in 2016. For the year ended December 31, 2017, the Company recorded $17,473 for the warrants issued to Mr. Rice in2016. On January 9, 2018, the Company extended the expiration date of the January 2015 Warrant from January 19, 2018 to January 31, 2020 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020. On April 26, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $20,000 per year and issue a one-time $20,000 bonus. Additionally, on August 15, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by an additional $20,000 per year. The salary increase and the bonus is accrued and to be paid in full earlier by the direction of the Board or upon the earlier of ●The Company maintaining $6,000,000 or more in working capital, ●Upon the transfer of ownership of more than 50% of the Corporation’s voting share or an assignment for the benefit of creditors or bankruptcy, or ●Upon the fifth year anniversary of the salary increase and the bonus issuance. As of December 31, 2019 and December 31, 2018 the Company owes $64,352 and $24,433, respectively, to Mr. Rice for payroll payable. On October 21, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $20,000 per year (effective August 15, 2019). The salary increase is accrued and to be paid in full earlier by the direction of the Board or upon the earlier of: ●The Company maintaining $6,000,000 or more in working capital, ●Upon the transfer of ownership of more than 50% of the Corporation’s voting share or an assignment for the benefit of creditors or bankruptcy, or ●Upon the fifth year anniversary of the salary increase and the bonus issuance. On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to annual cash compensation of $60,000. In addition, Mr. Le was issued two three-year warrants to purchase 2,000,000 shares of common stock of the Company at an exercise price of $0.2299 per share. As of December 31, 2019, the accrued salary balance is $1,154. (A) License Agreement On May 8, 2006, the Company entered into a license agreement. Pursuant to the terms of the agreement, the Company paid a non- refundable license fee of $10,000. The Company will pay a license maintenance fee of $10,000 on the one year anniversary of this agreement and each year thereafter. The Company will pay an annual research fee of $13,700 with first payment due January 2007, then on each subsequent anniversary of the effective date commencing May 4, 2007. The annual research fees are accrued by the Company for future payment. Pursuant to the terms of the agreement the Company may be required to pay additional fees aggregating up to a maximum of $10,000 a year for patent maintenance and prosecution relating to the licensed intellectual property. On October 28, 2011, the Company entered into a license agreement with the University of Notre Dame. Under the agreement, the Company received exclusive and non-exclusive rights to certain spider silk technologies including commercial rights with the right to sublicense such intellectual property. In consideration of the licenses granted under the agreement, the Company agreed to issue to the University of Notre Dame 2,200,000 shares of its common stock and to pay a royalty of 2% of net sales. The license agreement has a term of 20 years which can be extended on an annual basis after that. It can be terminated by the University of Notre Dame if the Company defaults on its obligations under the agreement and fails to cure such default within 90 days of a written notice by the university. The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years. On May 5, 2017, the Company signed an addendum to that agreement relating to tangible property and project intellectual property. On March 1, 2019, the Company singed an addendum to that agreement. The Company entered into a separate loan agreement and promissory noted dated March 1, 2019 as a payment for expenses paid by the University prior to January 31, 2019 totaling $265,244 and issued 4,025,652 shares of Class A common stock with a fair value of $281,659 as payment of certain debt. In the event of default the license agreement will be terminated. During the year ended December 31, 2019, the Company paid $20,000 of the balance (See Notes 6). (B) Royalty and Research Agreements On May 1, 2008 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company will be required to pay $1,000 per month, or at the Company’s option, the consulting fee may be paid in the form of Company common stock based upon the greater of $0.05 per share or the average of the closing price of the Company’s shares over the five days preceding such stock issuance. On April 6, 2018, the Company issued 36,000 shares with a fair value of $1,076 ($0.0299/share) to a consultant as consideration for consulting fees owed from October 1, 2014 through December 31, 2018 of $21,000. The issuance of shares resulted in gain on settlement of accounts payable of $19,924. On April 1, 2018, the Company ended the consulting agreement and no additional compensation will be issued. (See Note 7 (B)). On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. In accordance with FASB ASC No 480, Distinguishing Liabilities from Equity, On December 30, 2015, the Company entered into a cooperative agreement for the research and pilot production of hybrid silkworms in Vietnam. Under this agreement, the Company will establish a subsidiary in Vietnam where it will develop and produce hybrid silkworms. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. (C) Consulting Agreement On February 9, 2018, the Company issued a 3-year warrant to purchase 3,000,000 shares of common stock at an exercise price of $0.056 per share to a consultant for services rendered. The warrants had a fair value of $52,660, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Warrants will be exercisable on August 9, 2019, and for a period of 2 years expiring on August 9, 2021. During the year ended December 31, 2018, the Company recorded 52,660 as an expense for warrants issued (See Note 7 (C)). On February 20, 2018, the Company signed an agreement with a consultant to provide services. Under this agreement the consultant will receive a warrant for 600,000 shares of common stock and may be awarded additional warrants for up to 3,000,000 shares of common stock if performance metrics are achieved. On March 20, 2018, the Company issued a 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018. Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022. During the year ended December 31, 2018, the Company recorded $19,915 as an expense for warrants issued (See Note 7 (C)).’ On April 5, 2019, the Company cancelled 600,000 warrant issued to a consultant on February 20, 2018 in exchange for $6,000 cash payment. (D) Operating Lease Agreements Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $2,508 for conference facilities, mail, fax, and reception services located at our principal place of business. On May 9, 2019, the Company signed a 5 year property lease Socialist Republic of Vietnam which consists of 4,560.57 square meters of space, which it leases at a current rent of approximately $45,150 per year one and two and with the 5% increase per year for years three through five. On January 23, 2017, the Company signed an 8 year property lease with the Company’s President for land in Texas where the Company grows its mulberry. The Company pays a monthly rent of $960. Rent expense – related party for the years ended December 31, 2019 and 2018, was $14,793 and $11,520, respectively (See Note 9). On September 13, 2017, the Company signed a new two year lease commencing on October 1, 2017 and ending on December 31, 2019. The Company pays an annual rent of $39,200 for the year one of lease and $42,000 for the year two of lease for office and manufacturing space. On September 5, 2019, the Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters. The Company pays an annual rent of $42,000 for year one of the lease and $44,800 for year two of the lease.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 9 RELATED PARTY TRANSACTIONS On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. Pursuant to the addendum, the Company agreed to issue either 200,000 preferred shares with the following preferences; no dividends and voting rights equal to 100 common shares per share of preferred stock or the payment of $120,000, the officer agreed to terminate the royalty payments due under the agreement and give title to the exclusive license for the non-protective apparel use of the intellectual property to the Company. On the date of the agreement, the Company did not have any preferred stock authorized with the required preferences. In accordance with FASB ASC No. 480, Distinguishing Liabilities from Equity On November 10, 2010, the Company entered into an employment agreement, with its CEO, effective January 1, 2011 through the December 31, 2015. Subsequently, on January 1, 2018 the agreement renewed with the same terms for another 5 years with an annual salary of $334,708 for the year ended December 31, 2018. As of December 31, 2019 and December 31, 2018, the accrued salary balance is $2,464,244 and $2,109,454, respectively. On January 14, 2016 the Company signed a new employment agreement with Mr. Rice, the Company’s COO. The employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to annual cash compensation of $140,000, which includes salary, health insurance, 401K retirement plan contributions, etc. In addition, Mr. Rice was issued a three-year warrant to purchase 6,000,000 shares of common stock of the Company at an exercise price of $0.001 per share pursuant to the employment agreement. For the year ended December 31, 2016, the Company recorded $193,654 for the warrants issued to Mr. Rice. For the year ended December 31, 2017 the Company recorded $17,473 for the warrants issued to Mr. Rice in 2016. On January 9, 2018, the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 for Mr. Rice. On January 10, 2020, the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 31, 2020 to January 10, 2025 for Mr. Rice. Additionally, on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO. On April 26, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $20,000 per year and issue a one-time $20,000 bonus. On August 8, 2019 Mr. Rice was issued a set of three five-year warrant to purchase a total of 6,000,000 shares of common stock of the Company at an exercise price of $0.2299 per share pursuant to the employment agreement. Additionally, on August 15, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by an additional $20,000 per year. The salary increase and the bonus is accrued and to be paid in full earlier by the direction of the Board or upon the earlier of: ●The Company maintaining $6,000,000 or more in working capital, ●Upon the transfer of ownership of more than 50% of the Corporation’s voting share or an assignment for the benefit of creditors or bankruptcy, or ●Upon the fifth year anniversary of the salary increase and the bonus issuance. On October 21, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $20,000 per year (effective August 15, 2019). The salary increase is accrued and to be paid in full earlier by the direction of the Board or upon the earlier of: ●The Company maintaining $6,000,000 or more in working capital, ●Upon the transfer of ownership of more than 50% of the Corporation’s voting share or an assignment for the benefit of creditors or bankruptcy, or ●Upon the fifth year anniversary of the salary increase and the bonus issuance. As of December 31, 2019 and December 31, 2018, the Company owes $64,351 and $24,433, respectively, to Mr. Rice for payroll payable. On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Le at any time. Under the employment agreement, Mr. Le is entitled to an annual cash compensation of $60,000. In addition, Mr. Le was issued two three-year warrants to purchase 2,000,000 shares of common stock of the Company at an exercise price of $0.2299 per share. As of December 31, 2019, the accrued salary balance is $1,154. On June 6, 2016, the Company received a $50,000 loan from our principal stockholder. Subsequently on December 1, 2017, the Company received an additional $30,000 loan from the same stockholder. On January 8, 2018 and March 31, 2018 the Company received an additional loan of $100,000 and $15,000, respectively. The Company received additional loan funds from the same stockholder as follows: $20,000 on April 26, 2018; $15,000 on June 21, 2018; $15,000 on June 29, 2018; $20,000 on July 5, 2018; $26,000 on October 1, 2018; $11,000 on October 12, 2018; $20,000 on December 21, 2018; $3,000 on January 4, 2019; $30,000 on January 17, 2019; $30,000 on February 1, 2019; $20,000 on February 15, 2019; $20,000 on March 1, 2019; $17,000 on January 4, 2019, $100,000 on November 20, 2019, and $100,000 on December 18, 2019. Pursuant to the terms of the loan, the advance bears an interest at 3%, is unsecured, and due on demand. Total loan payable to principal stockholder for as of December 31, 2018 is $322,000. Total loan payable to this principal stockholder as of December 31, 2019 is $642,000. During the year ended December 31, 2019, the Company recorded $22,337 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $15,581. During the year ended December 31, 2018, the Company recorded $11,909 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $7,071. On January 23, 2017, the Company signed an 8 year property lease with the Company’s President for land in Texas. The Company pays $960 per month starting on February 1, 2017 and uses this facility to grow mulberry for its U.S. silk operations. Rent expense – related party for years ended December 31, 2019 and 2018 was $14,793 and $11,520, respectively. As of December 31, 2019 and December 31, 2018, there was $304,539 and $247,652, respectively, included in accounts payable and accrued expenses - related party, which is owed to the Company’s Chief Executive Officer and Chief Operations Officer. As of December 31, 2019, there was $1,196,503 of accrued interest- related party and $43,715 in shareholder loan interest – related party included in accounts payable and accrued expenses – related party, which is owed to the Company’s Chief Executive officer. As of December 31, 2018, there was $940,158 of accrued interest- related party and $28,135 in shareholder loan interest – related party included in accounts payable and accrued expenses – related party, which is owed to the Company’s Chief Executive officer. As of December 31, 2019, the Company owes $2,535,203in accrued salary to principal stockholder, $64,351 to the Company’s COO, $1,153 to Director of Prodigy Textiles and $4,477 to its office employees. As of December 31, 2018, the Company owes $2,109,454 in accrued salary to principal stockholder, $24,433 to the Company’s COO, and $7,640 to its office employees. The Company owes $65,292 in royalty payable to related party as of December 31, 2019 and December 31, 2018.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 SUBSEQUENT EVENTS The Company has analyzed its operations subsequent to December 31, 2019 through the date these financial statements were issued, and has determined that, other than disclosed below, it does not have any material subsequent events to disclose. On January 24, 2020, the Company received $100,000 from a principal stockholder. Pursuant to the terms of the loan, the advances bear an interest at 3%, is unsecured and due on demand. On February 19, 2020, the Board of Directors issued a total of 27,440,000 share options under the 2019 Employee Stock Option Plan. On February 19, 2020, the Company received $100,000 from a principal stockholder. Pursuant to the terms of the loan, the advances bear an interest at 3%, is unsecured and due on demand. On March 9, 2020, the Company received $100,000 from a principal stockholder. Pursuant to the terms of the loan, the advances bear an interest at 3%, is unsecured and due on demand. On March 19, 2020, the Company furloughed non-essential staff consistent with leading health official recommendations in order to help prevent the spread of COVID-19. This decision was made in an abundance of caution and will primarily impact staff at our fully owned subsidiary, Prodigy Textiles, in Vietnam and will result in the temporary closing of silk rearing operations at that facility. During the duration of the furlough, the Company CEO will not receive or accrue any pay.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Organization (Policies)	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	(A) Organization Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On October 8, 2019, the Company delivered the first batch of its transgenic silkworm eggs to its production factory in Quang Nam, Vietnam for the purpose of commencing production at that facility. On November 4, 2019, the Company reported that it had successfully completed rearing the first batch of its transgenic silkworms at its production factory in Quang Nam, Vietnam. The Company expects to continue expanding production of its specialized silk. In January 2020, the Company reported challenges related to climate and access to high quality mulberry during the winter months at its subsidiary in Vietnam. The Company announced that it had already begun planting additional mulberry fields to ensure no future shortages.
Foreign Currency	(B) Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.
Use of Estimates	(C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash	(D) Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents as of December 31, 2019 or December 31, 2018.
Loss Per Share	(E) Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For December 31, 2019 and December 31, 2018, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for December 31, 2019 and December 31, 2018 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: December 31, 2019 December 31, 2018 Stock Warrants (Exercise price - $0.001-$0.2299/share) 55,995,917 36,400,000 Convertible Preferred Stock 2 2 Total 55,995,919 36,400,002
Research and Development Costs	(F) Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.
Income Taxes	(G) Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: 2019 2018 Expected income tax recovery (expense) at the statutory rate of 21% $ (610,845 ) $ (1,412,328 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 142,167 11,057 Change in valuation allowance (468,678 ) (1,423,384 ) Provision for income taxes $ - $ - The components of deferred income taxes are as follows: Years Ended December, 2019 2018 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 3,379,542 2,910,863 Valuation allowance (3,379,542 ) (2,910,863 ) Net deferred tax asset - - Net deferred tax liability $ - $ - The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2039. The net change in the valuation allowance for the year ended December 31, 2019 and 2018 was an increase of $610,845 and a decrease of $1,412,328, respectively. Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
Stock-Based Compensation	(H) Stock-Based Compensation In December 2004, the FASB issued FASB ASC No. 718, Compensation – Stock Compensation Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by FASB ASC No. 718. FASB ASC No. 505, Equity Based Payments to Non-Employees
Recent Accounting Pronouncements	(I) Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11on its financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. The 2018 financial statements have been reclassified to conform to the 2019 presentation.
Equipment	(J) Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. The Company uses a five year life for automobiles. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no impairment losses recorded for the years ended December 31, 2019 and 2018.
Fair Value of Financial Instruments	(K) Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “ Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2019 and December 31, 2018. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. December 31, 2019 December 31, 2018 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ -
Revenue Recognition	(L) Revenue Recognition During the year ended December 31, 2018, the Company’s revenues were generated primarily from a contract with the U.S. Government. The Company performs work under this cost-plus-fixed-fee contract. Under the base phase of that contract the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017, to that original contract, the Company has worked to develop new recombinant silks. This contract ended in September of 2018. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC No. 605 — Revenue Recognition. Under ASC No. 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists;(2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. For the years ended December 31, 2019 and 2018, the Company recognized $0 and $401,620 respectively in revenue from the Government contract. These revenues were generated for work performed in the development and production of the Company’s recombinant silks under the base and option period phases of our ongoing contract with the US Army. On July 24, 2017, the Company signed a contract option extension with the US Army to research and deliver recombinant spider silk fibers and threads. This contract option increased the total contract award by an additional $921,130 to a total of $1,021,092 and added 12 months to the contract duration. This effort was scheduled to end on September 24, 2018, but the Company requested an extension of this contract option period through April 2019 to complete the work. The Company has been in communication with the contracting office and is working with them as they determine the best path forward; Management believes there is a possibility of securing a follow-up contract to complete the delivery of all materials for the contract. The Company is also continuing to pursue additional contract opportunities with the Department of Defense, Department of Energy and other governmental agencies.
Concentration of Credit Risk	(M) Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2019 and December 31, 2018, the Company had approximately $0 and $0, respectively in excess of FDIC insurance limits. For the years ended December 31, 2019 and 2018, the Company had a concentration of sales of: December 31, 2019 December 31, 2018 Customer Customer A - 100 % Customer A $ - $ 401,620 For the years ended December 31, 2019 and 2018, the Company booked $0 and $0 for doubtful accounts.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Organization (Tables)	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Antidilutive Securities of Earnings Per Share	The computation of basic and diluted loss per share for December 31, 2019 and December 31, 2018 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: December 31, 2019 December 31, 2018 Stock Warrants (Exercise price - $0.001-$0.2299/share) 55,995,917 36,400,000 Convertible Preferred Stock 2 2 Total 55,995,919 36,400,002
Schedule of Deferred Tax Assets and Liabilities	The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: 2019 2018 Expected income tax recovery (expense) at the statutory rate of 21% $ (610,845 ) $ (1,412,328 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 142,167 11,057 Change in valuation allowance (468,678 ) (1,423,384 ) Provision for income taxes $ - $ -
Schedule of Components of Deferred Income Taxes	The components of deferred income taxes are as follows: Years Ended December, 2019 2018 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 3,379,542 2,910,863 Valuation allowance (3,379,542 ) (2,910,863 ) Net deferred tax asset - - Net deferred tax liability $ - $ -
Schedule of Fair Value of Financial Instruments	December 31, 2019 December 31, 2018 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ -
Schedule of Concentration of Credit Risk	For the years ended December 31, 2019 and 2018, the Company had a concentration of sales of: December 31, 2019 December 31, 2018 Customer Customer A - 100 % Customer A $ - $ 401,620

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	At December 31, 2019 and December 31, 2018, property and equipment, net, is as follows: December 31, 2019 December 31, 2018 Automobile $ 41,805 $ 41,805 Laboratory Equipment 96,536 73,194 Office Equipment 7,260 7,260 Leasehold Improvements 85,388 7,938 Less: Accumulated Depreciation (113,668 ) (82,887 ) Total Property and Equipment, net $ 117,321 $ 47,310

Right to Use Assets and Lease_2

Right to Use Assets and Lease Liabilitity (Tables)	12 Months Ended
	Dec. 31, 2019
Right To Use Assets And Lease Liability
Schedule of Right Use of Assets	Right to use assets is summarized below: December 31, Right to use assets, net – related party $ 69,884 Right to use assets, net 53,799 Right to use assets, net 349,559 Total $ 473,242
Schedule of Lease Liability	Lease liability is summarized below: December 31, Right to use liability, net – related party 55,372 Right to use liability, net 70,901 Right to use liability, net 353,686 Total 479,959 Less: short term portion $ (110,678 ) Long term position $ 369,281
Schedule of Lease Cost	Lease expense for the year ended December 31, 2019 was comprised of the following: Operating lease expense $ 43,666 Operating lease expense $ 64,327 Operating lease expense – related party $ 14,793

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Option Assumption	On August 8, 2019, the Company issued a 2-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $267,574, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2024. During the year ended December 31, 2019, the Company recorded $267,574 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $267,574, based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2020. Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025. During the year ended December 31, 2019, the Company recorded $106,006 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 3-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $291,842, based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the year ended December 31, 2019, the Company recorded $57,889 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Years Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 1,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $118,874, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023. During the year ended December 31, 2019, the Company recorded $118,874 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 1,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $118,874, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2021, and for a period of 3 years expiring on August 8, 2024. During the year ended December 31, 2019, the Company recorded $118,874 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to an employee for services rendered. The options had a fair value of $14,859, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023. During the year ended December 31, 2019, the Company recorded $14,859 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $16,723, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2020. Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025. During the year ended December 31, 2019, the Company recorded $6,625, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $18,240, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the year ended December 31, 2019, the Company recorded $3,618, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Years Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $19,525, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2022. Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027. During the year ended December 31, 2019, the Company recorded $2,615, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Years Risk free interest rate 1.54 % Expected forfeitures 0 % On March 20, 2018, the Company issued a 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018. Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022. During the year ended December 31, 2018, the Company recorded $19,915 as an expense for warrants issued. On April 5, 2019, the Company cancelled 600,000 warrant issued to a consultant on February 20, 2018 in exchange for $6,000 cash payment. In addition the Company also recorded a $19,915 reduction to warrant expense related to the warrant cancellation. Expected dividends 0 % Expected volatility 97.56 % Expected term 4 Years Risk free interest rate 2.65 % Expected forfeitures 0 % On February 9, 2018, the Company issued a 3-year o to purchase 3,000,000 shares of common stock at an exercise price of $0.056 per share to a consultant for services rendered. The options had a fair value of $52,660, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 9, 2019, and for a period of 2 years expiring on August 9, 2021. During the year ended December 31, 2018, the Company recorded $52,660 as an expense for options issued. Expected dividends 0 % Expected volatility 96.95 % Expected term 3 Years Risk free interest rate 2.26 % Expected forfeitures 0 %
Schedule of Warrants Activity	Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Balance as of December 31, 2018 34,300,000 3.0 Granted 30,695,917 2.94 Exercised (9,000,000 ) Cancelled/Forfeited (600,000 ) Balance, December 31, 2019 55,395,917 2.77 Intrinsic Value $ 10,852,009
Schedule of Warrants Outstanding	For the year ended December 31, 2019, the following warrants were outstanding: Exercise Price Warrants Outstanding Warrants Exercisable Weighted Average Remaining Contractual Life Aggregate Intrinsic Value $ 0.001 21,000,000 1.65 $ 4,069,800 $ 0.056 3,000,000 1.61 $ 387,600 $ 0.04 2,300,000 1.70 $ 445,740 $ 0.06 7,398,639 1.19 $ 1,433,856 $ 0.06 7,398,639 2.19 $ 1,433,856 $ 0.08 3,699,320 2.19 $ 716,928 $ 0.08 3,699,320 3.19 $ 719,928 $ 0.2299 8,500,000 5.39 $ 1,647,300 For the year ended December 31, 2018, the following warrants were outstanding: Exercise Price Warrants Outstanding Warrants Exercisable Weighted Average Remaining Contractual Life Aggregate Intrinsic Value $ 0.001 29,600,000 2.9 $ 1,523,900 $ 0.056 3,000,000 2.6 $ 147,000 $ 0.04 2,300,000 2.7 $ 112,700

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Organization (Details Narrative)) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jul. 24, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash equivalents
Valuation allowance increase decrease	610,845	1,412,328
Government contract revenue		401,620
Contract award			$ 1,021,092
Additional contract award			$ 921,130
Cash excess of FDIC insurance limits	0	0
Doubtful accounts	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Organization - Schedule of Antidilutive Securities of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities	55,995,919	36,400,002
Stock Warrants [Member]
Antidilutive Securities	55,995,917	36,400,000
Convertible Preferred Stock [Member]
Antidilutive Securities	2	2

Summary of Significant Accoun_6

Summary of Significant Accounting Policies and Organization - Schedule of Antidilutive Securities of Earnings Per Share (Details) (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018	Mar. 20, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warrants exercise price	$ 0.001	$ 0.2299	$ 0.001

Summary of Significant Accoun_7

Summary of Significant Accounting Policies and Organization - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Expected income tax recovery (expense) at the statutory rate of 21%	$ (610,845)	$ (1,412,328)
Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes)	142,167	11,057
Change in valuation allowance	(468,678)	(1,423,384)
Provision for income taxes

Summary of Significant Accoun_8

Summary of Significant Accounting Policies and Organization - Schedule of Deferred Tax Assets and Liabilities (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Income tax rate	21.00%	21.00%

Summary of Significant Accoun_9

Summary of Significant Accounting Policies and Organization - Schedule of Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Operating Loss Carryforward	$ 3,379,542	$ 2,910,863
Valuation allowance	(3,379,542)	(2,910,863)
Net deferred tax asset
Net deferred tax liability

Summary of Significant Accou_10

Summary of Significant Accounting Policies and Organization - Schedule of Fair Value of Financial Instruments (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Fair value of assets and liabilities
Level 1 [Member]
Fair value of assets and liabilities
Level 2 [Member]
Fair value of assets and liabilities
Level 3 [Member]
Fair value of assets and liabilities

Summary of Significant Accou_11

Summary of Significant Accounting Policies and Organization - Schedule of Concentration of Credit Risk (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Sales		$ 401,620
Customer Concentration Risk [Member] | Customer A [Member]
Concentration risk		100.00%
Sales		$ 401,620

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$ (5,427,614)
Stockholders' deficiency	(5,388,058)	$ (4,459,223)	$ (3,375,806)
Cash used in operating activities	$ (1,087,881)	$ (235,005)

Equipment (Details Narrative)

Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 30,781	$ 26,632

Equipment - Schedule of Propert

Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Less: Accumulated Depreciation	$ (113,668)	$ (82,887)
Total Property and Equipment, net	117,321	47,310
Automobiles [Member]
Property and Equipment, gross	41,805	41,805
Laboratory Equipment [Member]
Property and Equipment, gross	96,536	73,194
Office Equipment [Member]
Property and Equipment, gross	7,260	7,260
Leasehold Improvements [Member]
Property and Equipment, gross	$ 85,388	$ 7,938

Right to Use Assets and Lease_3

Right to Use Assets and Lease Liability - (Details Narrative)	Sep. 05, 2019USD ($)ft²	May 09, 2019USD ($)ft²	Sep. 13, 2017USD ($)	Jan. 23, 2017USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)	Jan. 02, 2019USD ($)
Rent payments				$ 960			$ 2,508
Lease term			2 years	8 years
Annual rent, year one			$ 39,200
Annual rent, year two			$ 42,000
Lease Expiration			Dec. 31, 2019
Right of Use Assets					$ 473,242		473,242	$ 559,568
Lease liabilities					$ 110,678		$ 110,678	$ 559,568
Lease percentage					8.00%		8.00%
Lease Payments					$ 559,568
Lease expenses					75,575
Socialist Republic of Vietnam [Member]
Lease term		5 years
Annual rent, year one		$ 45,150
Annual rent, year two		$ 45,150
Area of Land | ft²		4,560.57
Socialist Republic of Vietnam [Member] | Three through Five Years [Member]
Rent increase percentage		5.00%
Research and Development Headquaters [Member]
Lease term	2 years
Annual rent, year one	$ 42,000
Annual rent, year two	$ 44,800
Lease Expiration	Sep. 30, 2021
Area of Land | ft²	5,000
Related Party [Member]
Rent payments					11,913	$ 5,760
Lease expenses					$ 11,913

Right to Use Assets and Lease_4

Right to Use Assets and Lease Liability - Schedule of Right Use of Assets (Details) - USD ($)	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Operating lease right-of-use asset, net	$ 473,242	$ 559,568
Right to Use Assets Net - Related Party [Member]
Operating lease right-of-use asset, net	69,884
Right to Use Assets Net [Member]
Operating lease right-of-use asset, net	53,799
Right to Use Assets Net One [Member]
Operating lease right-of-use asset, net	$ 349,559

Right to Use Assets and Lease_5

Right to Use Assets and Lease Liability - Schedule of Lease Liability (Details) - USD ($)	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Total	$ 479,959
Less: short term portion	(110,678)	$ (559,568)
Long term position	369,281
Right to Use Liability Net - Related Party [Member]
Total	55,372
Right to Use Liability Net [Member]
Total	70,901
Right to Use Liability Net One [Member]
Total	$ 353,686

Right to Use Assets and Lease_6

Right to Use Assets and Lease Liability - Schedule of Lease Cost (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Operating Lease Expenses [Member]
Lease expenses	$ 43,666
Operating Lease Expenses One [Member]
Lease expenses	64,327
Operating Lease Expenses - Related Party [Member]
Lease expenses	$ 14,793

Accrued Interest - Related Pa_2

Accrued Interest - Related Party (Details Narrative) - USD ($)	Dec. 18, 2019	Nov. 20, 2019	Mar. 01, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 01, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Mar. 31, 2018	Jan. 09, 2018	Dec. 01, 2017	Jun. 06, 2016	Dec. 31, 2019	Dec. 31, 2018
Proceeds from Debt	$ 100,000	$ 100,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 3,000	$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 15,000	$ 100,000	$ 30,000	$ 50,000
Debt Instrument, Interest rate																			3.00%
Loans payable amount																			$ 642,000	$ 322,000
In-kind contribution of interest																			22,337	11,909
Accrued interest																			$ 15,581	$ 7,071
Loan One [Member]
Proceeds from Debt							$ 17,000

Note Payable (Details Narrative

Note Payable (Details Narrative) - USD ($)	Mar. 01, 2019	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument, Interest rate		3.00%
Repayment of debt		$ 20,000
First Six Months [Member]
Repayment of debt		1,000
Seven and Eight Months [Member]
Repayment of debt		2,000
Nine Through Twenty Three Months [Member]
Repayment of debt		5,000
24th Month [Member]
Notes payable		$ 180,224
Unsecured Promissory Note [Member] | Notre Dame [Member]
Notes payable	$ 265,244
Debt Instrument, Interest rate	10.00%
Debt instrument, term	24 months

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)

Sep. 26, 2019

Aug. 14, 2019

Aug. 08, 2019

Apr. 04, 2019

Mar. 20, 2019

Mar. 09, 2019

Apr. 06, 2018

Mar. 20, 2018

Feb. 09, 2018

Aug. 08, 2020

Apr. 05, 2020

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2018

Mar. 08, 2019

Number of shares issued

766,667

7,967,871

4,052,652

36,000

Share price

$ 0.0695

$ 0.0299

$ 0.0299

$ 0.0299

$ 0.0299

Proceeds from issuance of common stock

$ 1,000,000

Warrants to purchase up share

1,000,000

8,000,000

600,000

Warrants exercise price

$ 0.001

$ 0.001

$ 0.2299

$ 0.2299

Number of shares issued, value

$ 281,659

$ 1,076

$ 1,000,000

Accounts payable

$ 19,924

Consulting fees

$ 342,845

$ 157,976

$ 21,000

Warrants term

4 years

Fair value of adjustments of warrants

$ 19,915

Warrants cancelled amount

$ 6,000

Number of warrants cancelled

600,000

University of Notre Dame [Member]

Number of shares issued, value

38,500

Accounts payable

$ 243,159

Common Stock and Warrants [Member]

Number of shares issued

14,797,278

6 Cent Warrants [Member]

Warrants to purchase up share

14,797,278

Warrants exercise price

$ 0.06

8 Cent Warrants [Member]

Warrants to purchase up share

7,398,639

Warrants exercise price

$ 0.08

Warrant [Member]

Warrants exercise price

$ 0.06

$ 0.001

$ 0.001

$ 0.001

Warrant expiration date

Mar. 8, 2021

Warrant One [Member]

Warrants exercise price

$ 0.06

0.056

0.056

0.056

Warrant expiration date

Mar. 8, 2022

Warrant Two [Member]

Warrants exercise price

$ 0.08

0.04

$ 0.04

$ 0.04

Warrant expiration date

Mar. 8, 2022

Warrant Three [Member]

Warrants exercise price

$ 0.08

$ 0.06

Warrant expiration date

Mar. 8, 2023

Common Stock Warrants and Options [Member]

Number of shares issued

2,000,000

Share price

$ 0.2299

Warrants to purchase up share

600,000

3,000,000

Warrants exercise price

$ 0.001

$ 0.056

Warrants term

4 years

3 years

Fair value of adjustments of warrants

$ 19,915

$ 52,660

Warrants cancelled amount

$ 6,000

Option term

2 years

Fair value of options

$ 267,574

Common stock warrants and options, description

Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022.

Options will be exercisable on August 9, 2019, and for a period of 2 years expiring on August 9, 2021.

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2024.

Share based compensation

$ 267,574

Warrants expenses

$ 19,915

Number of warrants cancelled

600,000

Common Stock Warrants and Options One [Member]

Number of shares issued

2,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 267,574

Common stock warrants and options, description

Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025.

Share based compensation

106,006

$ 52,660

Common Stock Warrants and Options Two [Member]

Number of shares issued

2,000,000

Share price

$ 0.2299

Option term

3 years

Fair value of options

$ 291,842

Common stock warrants and options, description

Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026.

Share based compensation

57,889

Common Stock Warrants and Options Three [Member]

Number of shares issued

1,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 118,874

Common stock warrants and options, description

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023.

Share based compensation

118,874

Common Stock Warrants and Options Four [Member]

Number of shares issued

1,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 118,874

Common stock warrants and options, description

Options will be exercisable on August 8, 2021, and for a period of 3 years expiring on August 8, 2024.

Share based compensation

118,874

Common Stock Warrants and Options Five [Member]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 14,859

Common stock warrants and options, description

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023.

Share based compensation

14,859

Common Stock Warrants and Options Six [Member]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 16,723

Common stock warrants and options, description

Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025.

Share based compensation

6,625

Common Stock Warrants and Options Seven [Member]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 18,240

Common stock warrants and options, description

Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026.

Share based compensation

3,618

Common Stock Warrants and Options Eight [Member]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 19,525

Common stock warrants and options, description

Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027.

Share based compensation

$ 2,615

Purchase Agreement [Member] | Investor [Member]

Number of shares issued

14,797,278

Share price

$ 0.06758

Proceeds from issuance of common stock

$ 1,000,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Option Assumption (Details)	Aug. 08, 2019	Mar. 20, 2018	Feb. 09, 2018
Common Stock Warrants and Options [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	2 years
Risk free interest rate	1.62%
Expected forfeitures	0.00%
Common Stock Warrants and Options One [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	2 years
Risk free interest rate	1.62%
Expected forfeitures	0.00%
Common Stock Warrants and Options Two [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	3 years
Risk free interest rate	1.54%
Expected forfeitures	0.00%
Common Stock Warrants and Options Three [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	2 years
Risk free interest rate	1.62%
Expected forfeitures	0.00%
Common Stock Warrants and Options Four [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	2 years
Risk free interest rate	1.62%
Expected forfeitures	0.00%
Common Stock Warrants and Options Five [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	2 years
Risk free interest rate	1.62%
Expected forfeitures	0.00%
Common Stock Warrants and Options Six [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	2 years
Risk free interest rate	1.62%
Expected forfeitures	0.00%
Common Stock Warrants and Options Seven [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	3 years
Risk free interest rate	1.54%
Expected forfeitures	0.00%
Common Stock Warrants and Options Eight [Member]
Expected dividends	0.00%
Expected volatility	105.73%
Expected term	3 years
Risk free interest rate	1.54%
Expected forfeitures	0.00%
Common Stock Warrants and Options Nine [Member]
Expected dividends		0.00%
Expected volatility		97.56%
Expected term		4 years
Risk free interest rate		2.65%
Expected forfeitures		0.00%
Common Stock Warrants and Options Ten [Member]
Expected dividends			0.00%
Expected volatility			96.95%
Expected term			3 years
Risk free interest rate			2.26%
Expected forfeitures			0.00%

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Warrants Activity (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Equity [Abstract]
Number of Warrants, Beginning balance | shares	34,300,000
Number of Warrants, Granted | shares	30,695,917
Number of Warrants, Exercised | shares	(9,000,000)
Number of Warrants, Cancelled/Forfeited | shares	(600,000)
Number of Warrants, Ending balance | shares	55,395,917
Number of Warrants, Intrinsic Value | $	$ 10,852,009
Weighted Average Exercise Price, Beginning balance
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled/Forfeited
Weighted Average Exercise Price, Ending balance
Weighted Average Exercise Price, Intrinsic Value
Weighted Average Remaining Contractual Life (In Years), Beginning balance	3 years
Weighted Average Remaining Contractual Life (In Years), Granted	2 years 11 months 8 days
Weighted Average Remaining Contractual Life (In Years), Ending balance	2 years 9 months 7 days

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Warrants Outstanding (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 09, 2019	Mar. 20, 2018
Exercise Price Warrants Outstanding	$ 0.001	$ 0.2299		$ 0.001
Weighted Average Remaining Contractual Life	3 years
Aggregate Intrinsic Value	$ 10,852,009
Warrant [Member]
Exercise Price Warrants Outstanding	$ 0.001	$ 0.001	$ 0.06
Warrants Exercisable	21,000,000	29,600,000
Weighted Average Remaining Contractual Life	1 year 7 months 24 days	2 years 10 months 25 days
Aggregate Intrinsic Value	$ 4,069,800	$ 1,523,900
Warrant One [Member]
Exercise Price Warrants Outstanding	$ 0.056	$ 0.056	0.06
Warrants Exercisable	3,000,000	3,000,000
Weighted Average Remaining Contractual Life	1 year 7 months 10 days	2 years 7 months 6 days
Aggregate Intrinsic Value	$ 387,600	$ 147,000
Warrant Two [Member]
Exercise Price Warrants Outstanding	$ 0.04	$ 0.04	0.08
Warrants Exercisable	2,300,000	2,300,000
Weighted Average Remaining Contractual Life	1 year 8 months 12 days	2 years 8 months 12 days
Aggregate Intrinsic Value	$ 445,740	$ 112,700
Warrant Three [Member]
Exercise Price Warrants Outstanding	$ 0.06		$ 0.08
Warrants Exercisable	7,398,639
Weighted Average Remaining Contractual Life	1 year 2 months 8 days
Aggregate Intrinsic Value	$ 1,433,856
Warrant Four [Member]
Exercise Price Warrants Outstanding	$ 0.06
Warrants Exercisable	7,398,639
Weighted Average Remaining Contractual Life	2 years 2 months 8 days
Aggregate Intrinsic Value	$ 1,433,856
Warrant Five [Member]
Exercise Price Warrants Outstanding	$ 0.08
Warrants Exercisable	3,699,320
Weighted Average Remaining Contractual Life	2 years 2 months 8 days
Aggregate Intrinsic Value	$ 716,928
Warrant Six [Member]
Exercise Price Warrants Outstanding	$ 0.08
Warrants Exercisable	3,699,320
Weighted Average Remaining Contractual Life	3 years 2 months 8 days
Aggregate Intrinsic Value	$ 719,928
Warrant Seven [Member]
Exercise Price Warrants Outstanding	$ 0.2299
Warrants Exercisable	8,500,000
Weighted Average Remaining Contractual Life	5 years 4 months 20 days
Aggregate Intrinsic Value	$ 1,647,300

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)

Jan. 09, 2020

Oct. 21, 2019

Sep. 26, 2019

Sep. 05, 2019

Aug. 15, 2019

Aug. 14, 2019

Jul. 03, 2019

May 09, 2019

Apr. 26, 2019

Apr. 05, 2019

Mar. 20, 2019

Jan. 30, 2019

Apr. 06, 2018

Mar. 20, 2018

Feb. 20, 2018

Feb. 09, 2018

Jan. 09, 2018

Sep. 13, 2017

Jan. 23, 2017

Jan. 14, 2016

Jan. 20, 2015

Oct. 28, 2011

Nov. 10, 2010

May 01, 2008

Dec. 26, 2006

May 08, 2006

Jan. 31, 2007

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2018

Dec. 31, 2019

Oct. 28, 2015

May 28, 2015

Annual salary

$ 627,197

$ 528,127

Warrant term

4 years

Warrant exercise price

$ 0.001

$ 0.001

$ 0.2299

$ 0.2299

$ 0.001

Working capital

$ (5,427,614)

$ (5,427,614)

Number of shares issued

766,667

7,967,871

4,052,652

36,000

Payment for debt

20,000

Stock issued during period, value

$ 281,659

$ 1,076

1,000,000

Consulting fee

342,845

157,976

$ 21,000

Interest expensed and related accrued interest payable

15,581

7,071

7,071

15,581

Fair value of warrants

$ 19,915

Payments for rent

$ 960

2,508

Mr. Jonathan R. Rice [Member]

Payroll payable

$ 64,352

$ 24,433

24,433

64,352

Employment Agreement [Member]

Extended expiration date description

The Company extended the expiration date of the January 2015 Warrant from January 19, 2018 to January 31, 2020 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020.

Employment Agreement [Member] | CEO [Member]

Agreement term

5 years

5 years

5 years

5 years

5 years

Annual salary

$ 210,000

$ 334,708

$ 354,791

$ 315,764

$ 297,889

$ 281,027

Annual salary rate, increase

6.00%

Accrued salary balance

2,535,203

2,109,454

2,109,454

2,535,203

Employment Agreement [Member] | Employee [Member]

Employee bonus rate

20.00%

Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]

Agreement term

1 year

Annual salary

$ 20,000

$ 20,000

$ 20,000

Annual cash compensation

$ 140,000

$ 120,000

Educational expenses

$ 11,000

Warrant term

3 years

Warrant to purchase shares

6,000,000

Warrant exercise price

$ 0.001

Warrant shares fully vested

2,000,000

Warrants issued value

17,473

$ 193,652

$ 121,448

Extended expiration date description

The Company extended the expiration date of the January 2015 Warrant from January 19, 2018 to January 31, 2020 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020.

Working capital

$ 6,000,000

$ 6,000,000

Ownership percentage

50.00%

50.00%

Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | One-Time Bonus [Member]

Annual salary

$ 20,000

Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | January 2015 Warrant [Member]

Warrant term

3 years

Warrant to purchase shares

2,000,000

Warrant exercise price

$ 0.001

Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | May 2015 Warrant [Member]

Warrant term

3 years

Warrant to purchase shares

3,000,000

Warrant exercise price

$ 0.001

Employment Agreement [Member] | Mr. Kenneth Le [Member]

Agreement term

1 year

Accrued salary balance

1,154

1,154

Annual cash compensation

$ 60,000

Warrant term

3 years

Warrant to purchase shares

2,000,000

Warrant exercise price

$ 0.2299

License Agreement [Member]

Agreement term

20 years

1 year

License fee

$ 10,000

License maintenance fee

$ 10,000

Annual research fee

$ 13,700

Number of shares issued

2,200,000

Royalty percentage

2.00%

Termination agreement description

The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years

Payment for debt

20,000

License Agreement [Member] | Maximum [Member]

Annual research fee

$ 10,000

License Agreement [Member] | Class A Common Stock [Member]

Number of shares issued

4,025,652

Payment for debt

$ 265,244

Stock issued during period, value

$ 281,659

Royalty and Research Agreements [Member]

Agreement term

5 years

Consulting fee

$ 1,000

Interest expensed and related accrued interest payable

6,543

6,543

Royalty and Research Agreements [Member] | Maximum [Member]

Shares issued, price per share

$ 0.05

Royalty and Research Agreements [Member] | Consultant [Member]

Number of shares issued

36,000

Stock issued during period, value

$ 1,076

Consulting fee

21,000

Shares issued, price per share

$ 0.0299

Gain on settlement of accounts payable

19,924

Royalty and Research Agreements [Member] | Mr. Thompson [Member]

Payment for debt

$ 120,000

Maturity date

Dec. 26, 2007

Outstanding balance

65,292

$ 65,292

$ 65,292

Interest expensed and related accrued interest payable

1,959

$ 1,959

Consulting Agreement [Member] | Consultant [Member]

Annual cash compensation

$ 6,000

Warrant term

4 years

3 years

Warrant to purchase shares

600,000

600,000

3,000,000

Warrant exercise price

$ 0.001

$ 0.056

Fair value of warrants

$ 19,915

$ 52,660

Warrants exercisable date

Mar. 20, 2019

Aug. 9, 2019

Warrants expiration date

Aug. 9, 2021

Warrants exercisable description

Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022.

Warrants will be exercisable on August 9, 2019, and for a period of 2 years expiring on August 9, 2021.

Warrants expenses

$ 19,915

$ 52,660

Cancelled warrant issued

600,000

Consulting Agreement [Member] | Consultant [Member] | Maximum [Member]

Warrant to purchase shares

3,000,000

Operating Lease Agreements [Member]

Payments for rent

$ 44,800

$ 39,200

2,508

Operating lease, term

2 years

5 years

2 years

Operating lease, description

The Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters.

The Company signed a 5 year property lease Socialist Republic of Vietnam which consists of 4,560.57 square meters of space, which it leases at a current rent of approximately $45,150 per year one and two and with the 5% increase per year for years three through five.

Operating leases, rent expense

14,793

$ 11,520

Operating Lease Agreements [Member] | Office and Manufacturing Space [Member]

Payments for rent

$ 42,000

Operating Lease Agreements [Member] | President [Member]

Payments for rent

$ 960

$ 960

Operating lease, term

8 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 09, 2020	Dec. 18, 2019	Nov. 20, 2019	Oct. 21, 2019	Sep. 26, 2019	Sep. 05, 2019	Aug. 15, 2019	Aug. 14, 2019	Jul. 03, 2019	Apr. 26, 2019	Mar. 20, 2019	Mar. 02, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 05, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 02, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Apr. 06, 2018	Mar. 31, 2018	Jan. 09, 2018	Jan. 08, 2018	Sep. 13, 2017	Jan. 23, 2017	Jun. 06, 2016	Jan. 14, 2016	Jan. 20, 2015	Nov. 10, 2010	Dec. 26, 2006	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 13, 2020	Dec. 31, 2019	Aug. 08, 2019	May 09, 2019	Mar. 20, 2018
Number of shares issued					766,667			7,967,871			4,052,652														36,000
Number of shares issued, value											$ 281,659														$ 1,076											$ 1,000,000
Accrued interest percentage																																				3.00%						3.00%
Interest expense and related accrued interest payable																																				$ 15,581	$ 7,071					$ 15,581
Annual salary																																				$ 627,197	$ 528,127
Warrant term																																													4 years
Warrant exercise price																																				$ 0.001	$ 0.2299					$ 0.001			$ 0.001
Working capital																																				$ (5,427,614)						$ (5,427,614)
Payments for rent																														$ 960												2,508
Related Party [Member]
Interest expense and related accrued interest payable																																				1,196,503	$ 940,158					1,196,503
Loan interest - related party																																				43,715	28,135					43,715
Royalty payable to related party																																				65,292	65,292
Mr. Jonathan R. Rice [Member]
Payroll payable																																				64,352	24,433					64,352
Stockholder [Member]
Outstanding balance																																				$ 22,337	11,909					$ 22,337
Accrued interest percentage																																				3.00%						3.00%
Interest expense and related accrued interest payable																																				$ 15,581	7,071					$ 15,581
Loan received		$ 100,000	$ 100,000									$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 17,000	$ 3,000	$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000		$ 15,000		$ 100,000			$ 50,000
Loans payable																																				642,000	322,000					642,000
Stockholder [Member] | Subsequent Event [Member]
Loan received																																									$ 30,000
Chief Executive Officer and Chief Operations Officer [Member]
Accounts payable and accrued expenses																																				304,539	247,652					304,539
Chief Operating Officer [Member]
Accrued salary balance																																				64,351	24,433					64,351
Directors [Member]
Accrued salary balance																																				1,153						1,153
Office Employee [Member]
Accrued salary balance																																				4,477	$ 7,640					4,477
Intellectual Property Transfer Agreement [Member] | Mr. Thompson [Member]
Number of shares issued																																			200,000
Dividends, preferred stock
Preferred stock voting rights																																			Voting rights equal to 100 common shares per share of preferred stock
Number of shares issued, value																																			$ 120,000
Fair value of the payment																																			$ 120,000
Maturity date																																			Dec. 26, 2007
Debt instrument, term																																			1 year
Outstanding balance																																				$ 65,292						$ 65,292
Accrued interest percentage																																				7.00%						7.00%
Interest expense and related accrued interest payable																																				$ 6,543						$ 6,543
Employment Agreement [Member]
Extended expiration date description	The Company extended the expiration date of the January 2015 Warrant from January 19, 2018 to January 31, 2020 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020.
Employment Agreement [Member] | CEO [Member]
Agreement term																																		5 years		5 years	5 years	5 years	5 years
Annual salary																																		$ 210,000		$ 334,708	$ 354,791	$ 315,764	$ 297,889	$ 281,027
Accrued salary balance																																				2,535,203	2,109,454					2,535,203
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]
Agreement term																																	1 year
Annual salary				$ 20,000			$ 20,000			$ 20,000
Annual cash compensation																																$ 140,000	$ 120,000
Warrant term																																3 years
Warrant to purchase shares																																6,000,000
Warrant exercise price																																$ 0.001
Warrants issued value																																						$ 17,473	$ 193,652	$ 121,448
Extended expiration date description																											The Company extended the expiration date of the January 2015 Warrant from January 19, 2018 to January 31, 2020 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020.
Working capital				$ 6,000,000			$ 6,000,000
Ownership percentage				50.00%			50.00%
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | One-Time Bonus [Member]
Annual salary										$ 20,000
Employment Agreement [Member] | Mr. Kenneth Le [Member]
Agreement term									1 year
Accrued salary balance																																				1,154						$ 1,154
Annual cash compensation									$ 60,000
Warrant term									3 years
Warrant to purchase shares									2,000,000
Warrant exercise price									$ 0.2299
New Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]
Working capital				$ 6,000,000
Ownership percentage				50.00%
New Employment Agreement [Member] | Mr. Rice [Member]
Warrant to purchase shares																																											6,000,000
Warrant exercise price																																											$ 0.2299
Operating Lease Agreements [Member]
Operating lease, term						2 years																							2 years															5 years
Payments for rent						$ 44,800																							$ 39,200							2,508
Operating Lease Agreements [Member] | President [Member]
Operating lease, term																														8 years
Payments for rent																														$ 960						960
Operating leases, rent expense																																				$ 14,793	$ 11,520

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 09, 2020	Feb. 19, 2020	Jan. 24, 2020	Dec. 31, 2019
Debt Instrument, Interest rate				3.00%
Subsequent Event [Member] | Principal Stockholder [Member]
Advances received from loan	$ 100,000	$ 100,000	$ 100,000
Debt Instrument, Interest rate	3.00%	3.00%	3.00%
Subsequent Event [Member] | Board of Directors [Member] | Employee Stock Option Plan [Member]
Share-based compensation, option		27,440,000